Vir and Alnylam Anticipate the Initiation of Clinical Study Assessing VIR-2703 By the Year End

 Vir and Alnylam Anticipate the Initiation of Clinical Study Assessing VIR-2703 By the Year End

Alnylam Reports Results of Givosiran in P-III ENVISION Study to Treat Acute Hepatic Porphyria

Shots:

  • The companies reported the selection of DC for VIR-2703 (ALN-COV) targeting SARS-CoV-2 genome and intend to meet US FDA & other regulatory authorities for IND filing with a plan to commence human studies by the end of 2020
  • In Oct, 2017, Alnylam and Vir entered into an exclusive license agreement to develop and commercialize RNAi therapeutics for infectious diseases, with an option to develop up to four additional infectious disease products
  • VIR-2703 is an inhaled siRNA targeting SARS-CoV-2 genome and is the first DC selected in Vir’s expanded collaboration with Alnylam for up to four RNAi potential therapeutics for COVID-19

Click here to­ read full press release/ article | Ref: Businesswire | Image: Alnylam

Related News: Vir and Alnylam Expand Their Existing Collaboration to Develop RNAi Therapeutics Targeting Host Factors for COVID-19

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post